Product Images Fulvestrant

This is a graph showing the Progression-Free Survival (ITT Population) over time in months for two different dosages of Fulvestrant (250mg and 500mg). The number of patients at risk for each dosage is also provided for each time period.*

The text is presenting data on the survival rate of patients who were treated with Fulvestrant. The data is separated based on whether the patients were treated with Fulvestrant at 500 mg or 250 mg. The presentation of the data is in the form of a graph, with the x-axis measuring time (in months) and the y-axis measuring the proportion of patients who were alive. The data indicates that the survival rate of patients was not significantly affected by the dose of Fulvestrant administered. The text mentions that there were no adjustments made for multiplicity during the study.*

This is a survival probability graph for patients treated with Fulvestrant and Palbociclib versus placebo. The X-axis represents the length of time in months from the start of treatment, while the Y-axis shows the probability of overall survival. The number of patients at risk is also displayed at different time points.*

This appears to be a table of data related to a clinical study evaluating the progression-free survival probability of two treatment groups (one group received fulvestrant plus abemaciclib and another group received fulvestrant plus placebo). The table includes information on the number of patients in each group (446 vs 223), censored observations, and patients at risk over different time periods (measured in months). It is not possible to tell what the study was aiming to treat or the results of the study from this table alone.*

The provided text appears to be a graph that displays the survival probability of two different treatments given to patients. On the graph, there are two lines, one for "Fulvestrant plus Abemaciclib" and the other for "Fulvestrant plus Placebo". The x-axis displays the time in months and the y-axis displays the survival probability as a percentage. The graph shows data for up to 57 months of treatment and displays the number of patients at risk at each timepoint for each of the treatments.*

This is a graph or diagram plotting time (months) and the effect of Fulvestrant+Ribociclib versus Fulvestrant+Placebo on patients. The number of patients at risk and events-ree probability (%) are also shown. However, without more context or clarification, it is not clear what these numbers represent or what the significance of the differences between the two groups is.*

This is a graph displaying the percentage of patients still present in the study over time. The data is from a clinical trial that used two treatments (Fulvestrant+Ribociclib and Fulvestrant+Placebo) on 484 and 242 patients, respectively. The study appears to have spanned a period of 48 months.*

This text appears to be a product identifier for "Fulvestrant Injection". It includes a code number NDG 70710-1688-2 and mentions the use of two single-dose prefilled syringes. Without further contextual information, it is difficult to provide a more detailed description.*

Fulvestrant Injection is a medication administered intramuscularly. It comes in 250mg/5mL (50mg/mL) doses and is contained in 2 single-dose pre-filled syringes. The label also includes manufacturing information and dosage instructions.*